Considerable progress in the classification of these different disorders in the same group of diseases derives from the introduction in the clinic of tumor necrosis factor-α (TNFα) inhibitors, demonstrating clinical benefit in a number of different diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and AS and this concept has been used to establish a cytokine-based disease taxonomy (7, 14). The gene discussed is TNF; the disease is psoriasis.